Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative biotechnology company focused on oncology, based in Sydney, Australia. The company is dedicated to developing cutting-edge anti-cancer drugs, with a robust pipeline aimed at addressing various forms of cancer.
The lead program for Kazia is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is primarily developed for treating glioblastoma multiforme, a highly aggressive brain cancer. Licensed from Genentech in late 2016, paxalisib has been the subject of numerous clinical trials. A Phase II study reported promising clinical activity, and the drug is currently undergoing pivotal trials, with additional studies targeting brain metastases and other central nervous system (CNS) cancers.
Besides paxalisib, Kazia is advancing EVT801, a small-molecule VEGFR3 inhibitor, licensed from Evotec SE in April 2021. EVT801 has shown preclinical efficacy across a range of tumor types and synergy with immuno-oncology agents. It's currently in Phase I clinical trials for advanced solid tumors.
Another notable drug in Kazia’s pipeline is Cantrixil (TRXE-002-1), under development for ovarian cancer and in Phase I clinical trials in Australia and the United States.
Kazia’s commitment to innovation and collaboration is evident through strategic partnerships and licensing agreements. For example, they recently signed a non-binding Letter of Intent with a biotechnology company to develop and commercialize paxalisib outside oncology, targeting epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex.
Financially, Kazia remains focused on securing funding to sustain its research and development endeavors. The company recently announced a direct offering expected to generate approximately $2 million.
Additionally, Kazia's forward-looking strategy includes addressing market listing requirements and ensuring compliance with Nasdaq’s Minimum Bid Price Requirement.
For more information, visit www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from its collaboration with the Huntsman Cancer Institute, showing that paxalisib is effective against preclinical models of metastatic melanoma. Dr. Gennie Parkman presented data indicating that paxalisib shows promise as a monotherapy and even greater efficacy in combination with existing therapies. With melanoma affecting about 100,000 Americans annually and a high mortality rate, further clinical trials for paxalisib in this area are anticipated in the near future, aiming to address unmet medical needs.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the international expansion of its phase II study of paxalisib, aimed at treating diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs). This study, sponsored by the Pacific Pediatric Neuro-Oncology Consortium, has recently opened two sites in Australia, marking its first trial in the country. The trial combines paxalisib with ONC201 and is currently active at nine sites in the U.S. and two in Australia, with plans for further international expansion. Initial data is anticipated in 2023.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced that CEO Dr. James Garner will present at the 24th Annual Global Investment Conference in New York from September 12-14, 2022. The presentation will highlight three positive data read-outs from Kazia's oncology programs in 2022 and discuss upcoming developments. The company's management team will also hold one-on-one meetings with institutional investors during the conference. Kazia is focused on developing treatments for aggressive brain cancers, including their lead program, paxalisib.
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be presented at the European Society for Medical Oncology (ESMO) annual congress in Paris, France from September 9-13, 2022. The presentation will detail findings previously highlighted at the ASCO Annual Meeting in June 2022. Professor John de Groot from the University of California, San Francisco will deliver the presentation, covering pharmacokinetics and pharmacodynamics.
Kazia Therapeutics reported busy FY22 results focusing on its oncology pipeline. The year featured positive data from preclinical and clinical programs, especially in childhood brain cancers. However, the lead asset paxalisib did not advance to Stage 2 in the Phase III GBM AGILE study for glioblastoma multiforme. The company's net cash at year-end stood at US$5.3m, needing an estimated US$50m more to reach break-even. Valuation remains at US$146.6m, with per basic ADR dropping to US$9.42 due to share count increase.
Kazia Therapeutics Limited (NASDAQ: KZIA) has revealed promising interim data from its phase I clinical trial of paxalisib in combination with radiotherapy for treating brain metastases. Conducted by Memorial Sloan Kettering Cancer Center, the trial showed a remarkable overall response rate of 100% in evaluable patients, compared to typical rates of 20-45% with standard radiotherapy. The data will be presented at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases in Toronto. Recruitment for the expansion stage of the trial is underway, aiming for an additional 12 patients.
Kazia Therapeutics Limited (NASDAQ: KZIA) has launched a new Scientific Advisory Board (SAB) to guide the development of its brain cancer treatment, paxalisib. The SAB includes four renowned experts in brain cancer research: Dr. Priscilla Brastianos, Dr. John de Groot, Dr. Alan Olivero, and Dr. Patrick Wen. Their expertise is crucial as paxalisib approaches the completion of the GBM AGILE clinical trial, anticipated in the second half of 2023. Kazia's CEO, Dr. James Garner, acknowledged the contributions of previous SAB members and emphasized the importance of this new team's guidance for the drug's potential commercialization.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced that the FDA granted Rare Pediatric Disease Designation (RPDD) for its drug paxalisib, targeting atypical rhabdoid/teratoid tumors, a rare and aggressive childhood brain cancer. This designation may lead to a pediatric priority review voucher (pPRV), which can significantly shorten the FDA review process and has historically been valued over $100 million. The RPDD follows positive preclinical results presented at the AACR Annual Meeting in April 2022. Kazia is advancing clinical trials, including a phase II study of paxalisib.
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced that the FDA has granted Orphan Drug Designation (ODD) for its drug, paxalisib, to treat atypical rhabdoid/teratoid tumors (AT/RT), a rare and aggressive childhood brain cancer. This designation provides advantages such as up to seven years of exclusivity and potential savings of over US$3 million in fees for regulatory filings. Paxalisib has previously received ODD for malignant glioma. The company continues its clinical studies to evaluate paxalisib’s efficacy in various brain cancers.
Kazia Therapeutics (NASDAQ: KZIA) announced promising new data on paxalisib at the 20th ISPNO in Hamburg. The research highlights paxalisib's effectiveness in treating childhood brain cancers with poor prognoses, specifically atypical teratoid/rhabdoid tumors and diffuse intrinsic pontine glioma (DIPG). Preclinical studies show that paxalisib, combined with ONC201, significantly extends survival in animal models. Two patients experienced dramatic tumor reduction with the combination therapy. A phase II clinical trial for this combination began recruitment in November 2021, with results anticipated in 1H CY2023.
FAQ
What is the current stock price of Kazia Therapeutics American Depositary Shares (KZIA)?
What is the market cap of Kazia Therapeutics American Depositary Shares (KZIA)?
What is Kazia Therapeutics’ primary focus?
What is paxalisib?
What stage are paxalisib’s clinical trials in?
What other drugs are in Kazia’s pipeline?
How is Kazia financing its projects?
What recent partnerships has Kazia formed?
What are the latest clinical trial developments for EVT801?
How does Kazia ensure compliance with Nasdaq’s listing requirements?
What is the significance of Kazia’s licensing agreement with Sovargen Co., Ltd?
Where can I find more information about Kazia Therapeutics?
